Oncternal Therapeutics, Inc. (ONCT)

NASDAQ: ONCT · IEX Real-Time Price · USD
1.69
0.02 (1.20%)
Jan 28, 2022 3:06 PM EST - Market open
Market Cap83.53M
Revenue (ttm)5.35M
Net Income (ttm)-25.82M
Shares Out49.43M
EPS (ttm)-0.58
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume168,938
Open1.65
Previous Close1.67
Day's Range1.62 - 1.73
52-Week Range1.62 - 10.56
Beta1.36
AnalystsStrong Buy
Price Target15.50 (+817.2%)
Earnings Daten/a

About ONCT

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor ty...

IndustryBiotechnology
CEOJames Breitmeyer
Employees12
Stock ExchangeNASDAQ
Ticker SymbolONCT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ONCT stock is "Strong Buy." The 12-month stock price forecast is 15.50, which is an increase of 817.16% from the latest price.

Price Target
$15.50
(817.16% upside)
Analyst Consensus: Strong Buy

News

Oncternal Therapeutics Hosting Key Opinion Leader Webinar on Hematological Malignancies and Prostate Cancer

SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

1 week ago - GlobeNewsWire

Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Study Design for Zilovertamab in t...

SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

3 weeks ago - GlobeNewsWire

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021

SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) --  Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ...

1 month ago - GlobeNewsWire

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

1 month ago - GlobeNewsWire

Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT-216 in Patients with Relapsed...

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

2 months ago - GlobeNewsWire

Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Conference

SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

2 months ago - GlobeNewsWire

Oncternal Therapeutics (ONCT) Reports Q3 Loss, Tops Revenue Estimates

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -18.75% and 64.07%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results

SAN DIEGO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today reporte...

2 months ago - GlobeNewsWire

Oncternal Therapeutics Joins Karolinska Institutet's NextGenNK Competence Center for the Development of Next Generati...

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

2 months ago - GlobeNewsWire

Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

2 months ago - GlobeNewsWire

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results

SAN DIEGO, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

2 months ago - GlobeNewsWire

Will Oncternal Therapeutics (ONCT) Report Negative Q3 Earnings? What You Should Know

Oncternal Therapeutics (ONCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Smal...

SAN DIEGO, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

3 months ago - GlobeNewsWire

Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

3 months ago - GlobeNewsWire

Oncternal Therapeutics to Participate in September Investor Conferences

SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ...

4 months ago - GlobeNewsWire

Oncternal Therapeutics Rounds Out Leadership Team with Appointment of Steven Hamburger, Ph.D. as Senior Vice Presiden...

SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announ...

4 months ago - GlobeNewsWire

Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of -14.29% and -18.99%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Recap: Oncternal Therapeutics Q2 Earnings

Shares of Oncternal Therapeutics (NASDAQ:ONCT) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 52.94% over the past year to ($0.16), whic...

5 months ago - Benzinga

Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today reporte...

5 months ago - GlobeNewsWire

Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced tha...

5 months ago - GlobeNewsWire

Will Oncternal Therapeutics (ONCT) Report Negative Q2 Earnings? What You Should Know

Oncternal Therapeutics (ONCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

5 months ago - GlobeNewsWire

Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development

SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announc...

6 months ago - GlobeNewsWire

Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference

SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that...

8 months ago - GlobeNewsWire

Oncternal Shares Jump After Encouraging Early Action In Soft-Tissue Sarcoma Trial With TK216

Oncternal Therapeutics Inc (NASDAQ: ONCT) has announced updated interim clinical data from its ongoing Phase 1/2 trial evaluating TK216 in relapsed or refractory Ewing sarcoma, or soft-tissue sarcoma. D...

8 months ago - Benzinga